{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:44:09Z","timestamp":1794473049119,"version":"4.9.1"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003061","name":"Erasmus Medisch Centrum","doi-asserted-by":"publisher","award":["Daniel Den Hoed Award"],"award-info":[{"award-number":["Daniel Den Hoed Award"]}],"id":[{"id":"10.13039\/501100003061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cancer remains a leading cause of mortality globally, driving ongoing research into innovative treatment strategies. Preclinical research forms the base for developing these novel treatments, using both in vitro and in vivo model systems that are, ideally, as clinically representative as possible. Emerging as a promising approach for cancer management, targeted radionuclide theranostics (TRT) uses radiotracers to deliver (cytotoxic) radionuclides specifically to cancer cells. Since the field is relatively new, more advanced preclinical models are not yet regularly applied in TRT research. This narrative review examines the currently applied in vitro, ex vivo and in vivo models for oncological research, discusses if and how these models are now applied for TRT studies, and whether not yet applied models can be of benefit for the field. A selection of different models is discussed, ranging from in vitro two-dimensional (2D) and three-dimensional (3D) cell models, including spheroids, organoids and tissue slice cultures, to in vivo mouse cancer models, such as cellline-derived models, patient-derived xenograft models and humanized models. Each of the models has advantages and limitations for studying human cancer biology, radiopharmaceutical assessment and treatment efficacy. Overall, there is a need to apply more advanced models in TRT research that better address specific TRT phenomena, such as crossfire and abscopal effects, to enhance the clinical relevance and effectiveness of preclinical TRT evaluations.<\/jats:p>","DOI":"10.1007\/s00259-025-07123-3","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T02:50:55Z","timestamp":1740711055000},"page":"3291-3311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Exploring the landscape of current in vitro and in vivo models and their relevance for targeted radionuclide theranostics"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4640-1395","authenticated-orcid":false,"given":"Lisa","family":"Bokhout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2401-1113","authenticated-orcid":false,"given":"Joana D.","family":"Campeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6393-6901","authenticated-orcid":false,"given":"Simone U.","family":"Dalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"7123_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"Cancer J Clin"},{"key":"7123_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, Bray F. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149:778\u201389. https:\/\/doi.org\/10.1002\/ijc.33588.","journal-title":"Int J Cancer"},{"key":"7123_CR3","doi-asserted-by":"publisher","unstructured":"Lepareur N, Ramee B, Mougin-Degraef M, Bourgeois M. Clinical advances and perspectives in targeted Radionuclide Therapy. Pharmaceutics. 2023;15. https:\/\/doi.org\/10.3390\/pharmaceutics15061733.","DOI":"10.3390\/pharmaceutics15061733"},{"key":"7123_CR4","doi-asserted-by":"publisher","first-page":"e220157","DOI":"10.1148\/rycan.220157","volume":"5","author":"BJ Burkett","year":"2023","unstructured":"Burkett BJ, Bartlett DJ, McGarrah PW, Lewis AR, Johnson DR, Berberoglu K, et al. A review of Theranostics: perspectives on emerging approaches and clinical advancements. Radiol Imaging Cancer. 2023;5:e220157. https:\/\/doi.org\/10.1148\/rycan.220157.","journal-title":"Radiol Imaging Cancer"},{"key":"7123_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fmed.2015.00012","volume":"2","author":"J-P Pouget","year":"2015","unstructured":"Pouget J-P, Lozza C, Deshayes E, Boudousq V, Navarro-Teulon I. Introduction to radiobiology of targeted radionuclide therapy. Front Med. 2015;2:12. https:\/\/doi.org\/10.3389\/fmed.2015.00012.","journal-title":"Front Med"},{"key":"7123_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2015.12.003","volume":"109","author":"S Aghevlian","year":"2017","unstructured":"Aghevlian S, Boyle AJ, Reilly RM. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting \u03b1-particles or Auger electrons. Adv Drug Deliv Rev. 2017;109:102\u201318. https:\/\/doi.org\/10.1016\/j.addr.2015.12.003.","journal-title":"Adv Drug Deliv Rev"},{"key":"7123_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.4149\/neo_2017_501","volume":"64","author":"M Widel","year":"2017","unstructured":"Widel M. Radionuclides in radiation-induced bystander effect; may it share in radionuclide therapy. Neoplasma. 2017;64:641\u201354. https:\/\/doi.org\/10.4149\/neo_2017_501.","journal-title":"Neoplasma"},{"key":"7123_CR8","doi-asserted-by":"publisher","first-page":"101084","DOI":"10.1016\/j.redox.2018.101084","volume":"25","author":"US Srinivas","year":"2019","unstructured":"Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. Redox Biol. 2019;25:101084. https:\/\/doi.org\/10.1016\/j.redox.2018.101084.","journal-title":"Redox Biol"},{"key":"7123_CR9","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2967\/jnumed.120.251512","volume":"62","author":"S Park","year":"2021","unstructured":"Park S, Parihar AS, Bodei L, Hope TA, Mallak N, Millo C, et al. Somatostatin Receptor Imaging and theranostics: current practice and future prospects. J Nucl Med. 2021;62:1323\u20139. https:\/\/doi.org\/10.2967\/jnumed.120.251512.","journal-title":"J Nucl Med"},{"key":"7123_CR10","unstructured":"FDA Letter of Approval for Netspot\u00ae. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2016\/208547Orig1s000ltr.pdf"},{"key":"7123_CR11","unstructured":"FDA Letter of Approval for Lutathera\u00ae. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2018\/208700Orig1s000ltr.pdf"},{"key":"7123_CR12","unstructured":"FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer. U.S. Food and Drug Administration. 2020. Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer"},{"key":"7123_CR13","unstructured":"FDA Letter of Approval for Pluvicto\u00ae. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2022\/215833Orig1s000ltr.pdf"},{"key":"7123_CR14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","volume":"39","author":"AA Fitzgerald","year":"2020","unstructured":"Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39:783\u2013803. https:\/\/doi.org\/10.1007\/s10555-020-09909-3.","journal-title":"Cancer Metastasis Rev"},{"key":"7123_CR15","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1007\/s00259-022-05870-1","volume":"49","author":"CD van der Heide","year":"2022","unstructured":"van der Heide CD, Dalm SU. Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine. Eur J Nucl Med Mol Imaging. 2022;49:4616\u201341. https:\/\/doi.org\/10.1007\/s00259-022-05870-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7123_CR16","doi-asserted-by":"publisher","unstructured":"Sun J, Huangfu Z, Yang J, Wang G, Hu K, Gao M, Zhong Z. Imaging-guided targeted radionuclide tumor therapy: from concept to clinical translation. Adv Drug Deliv Rev. 2022;114538. https:\/\/doi.org\/10.1016\/j.addr.2022.114538.","DOI":"10.1016\/j.addr.2022.114538"},{"key":"7123_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2967\/jnumed.116.176636","volume":"58","author":"SU Dalm","year":"2017","unstructured":"Dalm SU, Bakker IL, de Blois E, Doeswijk GN, Konijnenberg MW, Orlandi F, et al. 68Ga\/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology. J Nucl Med. 2017;58:293\u20139. https:\/\/doi.org\/10.2967\/jnumed.116.176636.","journal-title":"J Nucl Med"},{"key":"7123_CR18","doi-asserted-by":"publisher","first-page":"752","DOI":"10.2967\/jnumed.114.153023","volume":"56","author":"SU Dalm","year":"2015","unstructured":"Dalm SU, Martens JWM, Sieuwerts AM, van Deurzen CHM, Koelewijn SJ, de Blois E, et al. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer. J Nucl Med. 2015;56:752\u20137. https:\/\/doi.org\/10.2967\/jnumed.114.153023.","journal-title":"J Nucl Med"},{"key":"7123_CR19","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2967\/jnumed.115.160739","volume":"56","author":"SU Dalm","year":"2015","unstructured":"Dalm SU, Sieuwerts AM, Look MP, Melis M, van Deurzen CHM, Foekens JA, et al. Clinical relevance of targeting the gastrin-releasing peptide receptor, somatostatin receptor 2, or chemokine CXC motif receptor 4 in breast cancer for imaging and therapy. J Nucl Med. 2015;56:1487\u201393. https:\/\/doi.org\/10.2967\/jnumed.115.160739.","journal-title":"J Nucl Med"},{"key":"7123_CR20","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1007\/s00259-023-06364-4","volume":"50","author":"TST Damiana","year":"2023","unstructured":"Damiana TST, Para\u00efso P, de Ridder C, Stuurman D, Seimbille Y, Dalm SU. Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting. Eur J Nucl Med Mol Imaging. 2023;50:3851\u201361. https:\/\/doi.org\/10.1007\/s00259-023-06364-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7123_CR21","doi-asserted-by":"publisher","first-page":"102103","DOI":"10.1016\/j.scr.2020.102103","volume":"49","author":"DA Ovchinnikov","year":"2020","unstructured":"Ovchinnikov DA. Genetically-modified cell lines: categorisation and considerations for characterisation. Stem Cell Res. 2020;49:102103. https:\/\/doi.org\/10.1016\/j.scr.2020.102103.","journal-title":"Stem Cell Res"},{"key":"7123_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nmeth.3403","volume":"12","author":"LP Freedman","year":"2015","unstructured":"Freedman LP, Gibson MC, Ethier SP, Soule HR, Neve RM, Reid YA. Reproducibility: changing the policies and culture of cell line authentication. Nat Methods. 2015;12:493\u20137. https:\/\/doi.org\/10.1038\/nmeth.3403.","journal-title":"Nat Methods"},{"key":"7123_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","volume":"560","author":"U Ben-David","year":"2018","unstructured":"Ben-David U, Siranosian B, Ha G, Tang H, Oren Y, Hinohara K, et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018;560:325\u201330. https:\/\/doi.org\/10.1038\/s41586-018-0409-3.","journal-title":"Nature"},{"key":"7123_CR24","doi-asserted-by":"publisher","first-page":"FSO190","DOI":"10.4155\/fsoa-2017-0003","volume":"3","author":"TG Meijer","year":"2017","unstructured":"Meijer TG, Naipal KAT, Jager A, van Gent DC. Ex vivo tumor culture systems for functional drug testing and therapy response prediction. Future Sci OA. 2017;3:FSO190. https:\/\/doi.org\/10.4155\/fsoa-2017-0003.","journal-title":"Future Sci OA"},{"key":"7123_CR25","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/jnci\/51.5.1417","volume":"51","author":"DJ Giard","year":"1973","unstructured":"Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973;51:1417\u201323. https:\/\/doi.org\/10.1093\/jnci\/51.5.1417.","journal-title":"J Natl Cancer Inst"},{"key":"7123_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1530\/ERC-17-0445","volume":"25","author":"T Hofving","year":"2018","unstructured":"Hofving T, Arvidsson Y, Almobarak B, Inge L, Pfragner R, Persson M, et al. The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines. Endocrine-related Cancer. 2018;25:367\u201380. https:\/\/doi.org\/10.1530\/ERC-17-0445.","journal-title":"Endocrine-related Cancer"},{"key":"7123_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11154-020-09607-z","volume":"22","author":"MJ Klomp","year":"2021","unstructured":"Klomp MJ, Dalm SU, De Jong M, Feelders RA, Hofland J, Hofland LJ. Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer. Reviews Endocr Metabolic Disorders. 2021;22:495\u2013510. https:\/\/doi.org\/10.1007\/s11154-020-09607-z.","journal-title":"Reviews Endocr Metabolic Disorders"},{"key":"7123_CR28","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/0196-9781(94)90146-5","volume":"15","author":"JE Taylor","year":"1994","unstructured":"Taylor JE, Theveniau MA, Bashirzadeh R, Reisine T, Eden PA. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides. 1994;15:1229\u201336. https:\/\/doi.org\/10.1016\/0196-9781(94)90146-5.","journal-title":"Peptides"},{"key":"7123_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000338793","volume":"96","author":"S Grozinsky-Glasberg","year":"2012","unstructured":"Grozinsky-Glasberg S, Shimon I, Rubinfeld H. The role of cell lines in the study of neuroendocrine tumors. Neuroendocrinology. 2012;96:173\u201387. https:\/\/doi.org\/10.1159\/000338793.","journal-title":"Neuroendocrinology"},{"key":"7123_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.cancergen.2015.04.002","volume":"208","author":"GK Boora","year":"2015","unstructured":"Boora GK, Kanwar R, Kulkarni AA, Pleticha J, Ames M, Schroth G, et al. Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines. Cancer Genet. 2015;208:374\u201381. https:\/\/doi.org\/10.1016\/j.cancergen.2015.04.002.","journal-title":"Cancer Genet"},{"key":"7123_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ajpath.2011.10.036","volume":"180","author":"X Liu","year":"2012","unstructured":"Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol. 2012;180:599\u2013607. https:\/\/doi.org\/10.1016\/j.ajpath.2011.10.036.","journal-title":"Am J Pathol"},{"key":"7123_CR32","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.apsb.2020.01.011","volume":"10","author":"X Wu","year":"2020","unstructured":"Wu X, Wang S, Li M, Li J, Shen J, Zhao Y, et al. Conditional reprogramming: next generation cell culture. Acta Pharm Sinica B. 2020;10:1360\u201381. https:\/\/doi.org\/10.1016\/j.apsb.2020.01.011.","journal-title":"Acta Pharm Sinica B"},{"key":"7123_CR33","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/pros.23206","volume":"76","author":"L Ellis","year":"2016","unstructured":"Ellis L, Ku S, Li Q, Azabdaftari G, Seliski J, Olson B, et al. Generation of a C57BL\/6 MYC-driven mouse model and cell line of prostate cancer. Prostate. 2016;76:1192\u2013202. https:\/\/doi.org\/10.1002\/pros.23206.","journal-title":"Prostate"},{"key":"7123_CR34","doi-asserted-by":"publisher","first-page":"22741","DOI":"10.18632\/oncotarget.13937","volume":"8","author":"OA Timofeeva","year":"2017","unstructured":"Timofeeva OA, Palechor-Ceron N, Li G, Yuan H, Krawczyk E, Zhong X, et al. Conditionally reprogrammed normal and primary tumor prostate epithelial cells: a novel patient-derived cell model for studies of human prostate cancer. Oncotarget. 2017;8:22741. https:\/\/doi.org\/10.18632\/oncotarget.13937.","journal-title":"Oncotarget"},{"key":"7123_CR35","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1158\/2767-9764.CRC-22-0203","volume":"2","author":"M Jung","year":"2022","unstructured":"Jung M, Kowalczyk K, Hankins R, Bandi G, Kallakury B, Carrasquilla MA, et al. Novel paired normal prostate and prostate cancer model cell systems derived from African American patients. Cancer Res Commun. 2022;2:1617\u201325. https:\/\/doi.org\/10.1158\/2767-9764.CRC-22-0203.","journal-title":"Cancer Res Commun"},{"key":"7123_CR36","doi-asserted-by":"publisher","first-page":"11503","DOI":"10.18632\/oncotarget.23817","volume":"9","author":"L Jin","year":"2018","unstructured":"Jin L, Qu Y, Gomez LJ, Chung S, Han B, Gao B, et al. Characterization of primary human mammary epithelial cells isolated and propagated by conditional reprogrammed cell culture. Oncotarget. 2018;9:11503. https:\/\/doi.org\/10.18632\/oncotarget.23817.","journal-title":"Oncotarget"},{"key":"7123_CR37","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1007\/s11033-021-06513-8","volume":"48","author":"M Gr\u00f6nman","year":"2021","unstructured":"Gr\u00f6nman M, Moisio O, Li XG, Toimela T, Huttala O, Heinonen T, et al. Association between [68Ga]NODAGA-RGDyK uptake and dynamics of angiogenesis in a human cell-based 3D model. Mol Biol Rep. 2021;48:5347\u201353. https:\/\/doi.org\/10.1007\/s11033-021-06513-8.","journal-title":"Mol Biol Rep"},{"key":"7123_CR38","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1007\/s00259-023-06333-x","volume":"50","author":"CD Van Der Heide","year":"2023","unstructured":"Van Der Heide CD, Lak A, McMorrow R, Mezzanotte L, Dalm SU. Novel co-culture model of pancreatic Cancer to accurately predict the efficacy of fibroblast activation protein targeted Radionuclide Therapy using [161\u00a0tb]Tb- FAP-2286 and [177Lu]Lu-FAP-2286. Eur J Nucl Med Mol Imaging. 2023;50:S187\u20138. https:\/\/doi.org\/10.1007\/s00259-023-06333-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7123_CR39","doi-asserted-by":"publisher","unstructured":"Shi D, Si Z, Cheng Y, Cheng D, Shi H. Synthesis and evaluation of 68Ga-NOTACOG1410 targeting to TREM2 of TAMs as a specific PET probe for Digestive Tumor diagnosis. J Nucl Med. 2023;63. https:\/\/doi.org\/10.1021\/acs.analchem.1c04701.","DOI":"10.1021\/acs.analchem.1c04701"},{"key":"7123_CR40","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","volume":"50","author":"BM Priv\u00e9","year":"2023","unstructured":"Priv\u00e9 BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre) clinical studies. Eur J Nucl Med Mol Imaging. 2023;50:1906\u201318. https:\/\/doi.org\/10.1007\/s00259-023-06144-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7123_CR41","doi-asserted-by":"publisher","first-page":"910","DOI":"10.5114\/aoms.2016.63743","volume":"14","author":"M Kapa\u0142czy\u0144ska","year":"2018","unstructured":"Kapa\u0142czy\u0144ska M, Kolenda T, Przyby\u0142a W, Zaj\u0105czkowska M, Teresiak A, Filas V, et al. 2D and 3D cell cultures\u2013a comparison of different types of cancer cell cultures. Archives Med Sci. 2018;14:910\u20139. https:\/\/doi.org\/10.5114\/aoms.2016.63743.","journal-title":"Archives Med Sci"},{"key":"7123_CR42","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s42003-020-0973-6","volume":"3","author":"S Lagies","year":"2020","unstructured":"Lagies S, Schlimpert M, Neumann S, W\u00e4ldin A, Kammerer B, Borner C, Peintner L. Cells grown in three-dimensional spheroids mirror in vivo metabolic response of epithelial cells. Commun Biology. 2020;3:246. https:\/\/doi.org\/10.1038\/s42003-020-0973-6.","journal-title":"Commun Biology"},{"key":"7123_CR43","doi-asserted-by":"crossref","unstructured":"Foty R. A simple hanging drop cell culture protocol for generation of 3D spheroids. JoVE (Journal Visualized Experiments). 2011;e2720. https:\/\/doi.org\/10.3791%2F2720.","DOI":"10.3791\/2720-v"},{"key":"7123_CR44","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2144\/000112591","volume":"43","author":"AP Napolitano","year":"2007","unstructured":"Napolitano AP, Dean DM, Man AJ, Youssef J, Ho DN, Rago AP, et al. Scaffold-free three-dimensional cell culture utilizing micromolded nonadhesive hydrogels. Biotechniques. 2007;43:494\u2013500. https:\/\/doi.org\/10.2144\/000112591.","journal-title":"Biotechniques"},{"key":"7123_CR45","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1002\/bit.25210","volume":"111","author":"EC Costa","year":"2014","unstructured":"Costa EC, Gaspar VM, Coutinho P, Correia IJ. Optimization of liquid overlay technique to formulate heterogenic 3D co-cultures models. Biotechnol Bioeng. 2014;111:1672\u201385. https:\/\/doi.org\/10.1002\/bit.25210.","journal-title":"Biotechnol Bioeng"},{"key":"7123_CR46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3389\/fonc.2013.00215","volume":"3","author":"D Brady","year":"2013","unstructured":"Brady D, O\u2019Sullivan JM, Prise KM. What is the role of the bystander response in radionuclide therapies? Front Oncol. 2013;3:215. https:\/\/doi.org\/10.3389\/fonc.2013.00215.","journal-title":"Front Oncol"},{"key":"7123_CR47","doi-asserted-by":"publisher","first-page":"045209","DOI":"10.1088\/2057-1976\/1\/4\/045209","volume":"1","author":"DR Grimes","year":"2015","unstructured":"Grimes DR, Partridge M. A mechanistic investigation of the oxygen fixation hypothesis and oxygen enhancement ratio. Biomed Phys Eng Express. 2015;1:045209. https:\/\/doi.org\/10.1088\/2057-1976\/1\/4\/045209.","journal-title":"Biomed Phys Eng Express"},{"key":"7123_CR48","doi-asserted-by":"publisher","unstructured":"Jones B. The influence of hypoxia on LET and RBE relationships with implications for ultra-high dose rates and FLASH modelling. Phys Med Biol. 2022;67. https:\/\/doi.org\/10.1088\/1361-6560\/ac6ebb.","DOI":"10.1088\/1361-6560\/ac6ebb"},{"key":"7123_CR49","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.3390\/cancers13164046","volume":"13","author":"E Refet-Mollof","year":"2021","unstructured":"Refet-Mollof E, Najyb O, Chermat R, Glory A, Lafontaine J, Wong P, Gervais T. Hypoxic jumbo spheroids On-A-Chip (HOnAChip): insights into treatment efficacy. Cancers. 2021;13:4046. https:\/\/doi.org\/10.3390\/cancers13164046.","journal-title":"Cancers"},{"key":"7123_CR50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12935-022-02810-9","volume":"22","author":"K Sekihara","year":"2022","unstructured":"Sekihara K, Himuro H, Saito N, Ota Y, Kouro T, Kusano Y, et al. Evaluation of X-ray and carbon-ion beam irradiation with chemotherapy for the treatment of cervical adenocarcinoma cells in 2D and 3D cultures. Cancer Cell Int. 2022;22:391. https:\/\/doi.org\/10.1186\/s12935-022-02810-9.","journal-title":"Cancer Cell Int"},{"key":"7123_CR51","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/pros.20502","volume":"66","author":"J Wang","year":"2006","unstructured":"Wang J, Abbas Rizvi SM, Madigan MC, Cozzi PJ, Power CA, Qu CF, et al. Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted \u03b1 radioimmunoconjugates. Prostate. 2006;66:1753\u201367. https:\/\/doi.org\/10.1002\/pros.20502.","journal-title":"Prostate"},{"key":"7123_CR52","doi-asserted-by":"publisher","unstructured":"Raitanen J, Barta B, Fuchs H, Hacker M, Balber T, Georg D, Mitterhauser M. Radiobiological Assessment of targeted Radionuclide Therapy with [177Lu]Lu-PSMA-I&T in 2D vs. 3D cell culture models. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms242317015.","DOI":"10.3390\/ijms242317015"},{"key":"7123_CR53","doi-asserted-by":"publisher","unstructured":"Salerno D, Howe A, Bhatavdekar O, Josefsson A, Pacheco-Torres J, Bhujwalla ZM, et al. Two diverse carriers are better than one: a case study in \u03b1-particle therapy for prostate specific membrane antigen-expressing prostate cancers. Bioeng Translational Med. 2022;7. https:\/\/doi.org\/10.1002\/btm2.10266.","DOI":"10.1002\/btm2.10266"},{"key":"7123_CR54","doi-asserted-by":"publisher","unstructured":"Stenberg VY, Larsen RH, Ma LW, Peng Q, Juzenas P, Bruland \u00d8S, Juzeniene A. Evaluation of the psma-binding ligand212pb-ng001 in multicellular tumour spheroid and mouse models of prostate cancer. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22094815.","DOI":"10.3390\/ijms22094815"},{"key":"7123_CR55","doi-asserted-by":"publisher","unstructured":"Tornes AJK, Stenberg VY, Larsen RH, Bruland \u00d8S, Revheim ME, Juzeniene A. Targeted alpha therapy with the 224Ra\/212Pb-TCMC-TP-3 dual alpha solution in a multicellular tumor spheroid model of osteosarcoma. Front Med. 2022;9. https:\/\/doi.org\/10.3389\/fmed.2022.1058863.","DOI":"10.3389\/fmed.2022.1058863"},{"key":"7123_CR56","doi-asserted-by":"publisher","unstructured":"Mohajershojai T, Jha P, Bostr\u00f6m A, Frejd FY, Yazaki PJ, Nestor M. In Vitro characterization of 177Lu-DOTA-M5A anti-carcinoembryonic Antigen Humanized antibody and HSP90 inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.849338.","DOI":"10.3389\/fonc.2022.849338"},{"key":"7123_CR57","doi-asserted-by":"publisher","unstructured":"Lundsten S, Berglund H, Jha P, Krona C, Hariri M, Nelander S, et al. P53-mediated radiosensitization of177lu-dotatate in neuroblastoma tumor spheroids. Biomolecules. 2021;11. https:\/\/doi.org\/10.3390\/biom11111695.","DOI":"10.3390\/biom11111695"},{"key":"7123_CR58","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.3390\/cancers16142515","volume":"16","author":"TGA Reuvers","year":"2024","unstructured":"Reuvers TGA, Grandia V, Brandt RMC, Arab M, Maas SLN, Bos EM, Nonnekens J. Investigating the Radiobiological response to peptide receptor Radionuclide Therapy using patient-derived Meningioma Spheroids. Cancers. 2024;16:2515. https:\/\/doi.org\/10.3390\/cancers16142515.","journal-title":"Cancers"},{"key":"7123_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13061421","volume":"13","author":"H Akil","year":"2021","unstructured":"Akil H, Quintana M, Raymond JH, Billoux T, Benboubker V, Besse S, et al. Efficacy of targeted radionuclide therapy using [131I]ICF01012 in 3D pigmented BRAF-and NRAS-mutant melanoma models and in vivo NRAS-mutated melanoma. Cancers. 2021;13:1\u201320. https:\/\/doi.org\/10.3390\/cancers13061421.","journal-title":"Cancers"},{"key":"7123_CR60","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3892\/ijo.2019.4888","volume":"55","author":"S Lundsten","year":"2019","unstructured":"Lundsten S, Spiegelberg D, Stenerl\u00f6w B, Nestor M. The HSP90 inhibitor onalespib potentiates 177Lu\u2013DOTATATE therapy in neuroendocrine tumor cells. Int J Oncol. 2019;55:1287\u201395. https:\/\/doi.org\/10.3892\/ijo.2019.4888.","journal-title":"Int J Oncol"},{"key":"7123_CR61","doi-asserted-by":"publisher","unstructured":"\u017buk M, Podg\u00f3rski R, Ruszczy\u0144ska A, Ciach T, Majkowska-Pilip A, Bilewicz A, Krysi\u0144ski P. Multifunctional nanoparticles based on Iron oxide and Gold-198 designed for magnetic hyperthermia and Radionuclide Therapy as a potential Tool for Combined HER2-Positive Cancer treatment. Pharmaceutics. 2022;14. https:\/\/doi.org\/10.3390\/pharmaceutics14081680.","DOI":"10.3390\/pharmaceutics14081680"},{"key":"7123_CR62","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2967\/jnumed.117.207308","volume":"60","author":"N Falzone","year":"2019","unstructured":"Falzone N, Lee BQ, Able S, Malcolm J, Terry S, Alayed Y, Vallis KA. Targeting micrometastases: the effect of heterogeneous radionuclide distribution on tumor control probability. J Nucl Med. 2019;60:250\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.207308.","journal-title":"J Nucl Med"},{"key":"7123_CR63","doi-asserted-by":"publisher","unstructured":"Marshall SK, Taweesap M, Saelim B, Pachana V, Benlateh N, Sangangam S, et al. Cytotoxicity enhancement in Osteosarcoma with multifunctional I-131 Radiotherapeutic nanoparticles: in Vitro three-dimensional spheroid model and release kinetics modeling. Molecules. 2024;29. https:\/\/doi.org\/10.3390\/molecules29030630.","DOI":"10.3390\/molecules29030630"},{"key":"7123_CR64","doi-asserted-by":"publisher","first-page":"20662","DOI":"10.1038\/s41598-023-47287-2","volume":"13","author":"T Peke\u010d","year":"2023","unstructured":"Peke\u010d T, Venkatachalapathy S, Shim AR, Paysan D, Grzmil M, Schibli R, et al. Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers. Sci Rep. 2023;13:20662. https:\/\/doi.org\/10.1038\/s41598-023-47287-2.","journal-title":"Sci Rep"},{"key":"7123_CR65","doi-asserted-by":"publisher","unstructured":"Mortensen ACL, Morin E, Brown CJ, Lane DP, Nestor M. Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2\/X-p53 antagonist PM2. EJNMMI Res. 2020;10. https:\/\/doi.org\/10.1186\/s13550-020-0613-7.","DOI":"10.1186\/s13550-020-0613-7"},{"key":"7123_CR66","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.tranon.2019.07.015","volume":"12","author":"H Akil","year":"2019","unstructured":"Akil H, Rouanet J, Viallard C, Besse S, Auzeloux P, Chezal JM, et al. Targeted Radionuclide Therapy decreases Melanoma Lung Invasion by modifying epithelial-mesenchymal transition-like mechanisms. Translational Oncol. 2019;12:1442\u201352. https:\/\/doi.org\/10.1016\/j.tranon.2019.07.015.","journal-title":"Translational Oncol"},{"key":"7123_CR67","doi-asserted-by":"publisher","first-page":"115152","DOI":"10.1016\/j.biopha.2023.115152","volume":"165","author":"M \u015awierczewska","year":"2023","unstructured":"\u015awierczewska M, Sterzy\u0144ska K, Ruci\u0144ski M, Andrzejewska M, Nowicki M, Januchowski R. The response and resistance to drugs in ovarian cancer cell lines in 2D monolayers and 3D spheroids. Biomed Pharmacother. 2023;165:115152. https:\/\/doi.org\/10.1016\/j.biopha.2023.115152.","journal-title":"Biomed Pharmacother"},{"key":"7123_CR68","doi-asserted-by":"publisher","first-page":"e0244513","DOI":"10.1371\/journal.pone.0244513","volume":"16","author":"J Koch","year":"2021","unstructured":"Koch J, Moench D, Maass A, Gromoll C, Hehr T, Leibold T, et al. Three dimensional cultivation increases chemo-and radioresistance of colorectal cancer cell lines. PLoS ONE. 2021;16:e0244513. https:\/\/doi.org\/10.1371\/journal.pone.0244513.","journal-title":"PLoS ONE"},{"key":"7123_CR69","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1002\/mco2.274","volume":"4","author":"S Yang","year":"2023","unstructured":"Yang S, Hu H, Kung H, Zou R, Dai Y, Hu Y, et al. Organoids: the current status and biomedical applications. MedComm. 2023;4:e274. https:\/\/doi.org\/10.1002\/mco2.274.","journal-title":"MedComm"},{"key":"7123_CR70","doi-asserted-by":"publisher","unstructured":"Zhao Z, Chen X, Dowbaj AM, Sljukic A, Bratlie K, Lin L, et al. Organoids Nat Reviews Methods Primers. 2022;2:94. https:\/\/doi.org\/10.1038\/s43586-022-00174-y.","DOI":"10.1038\/s43586-022-00174-y"},{"key":"7123_CR71","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","volume":"21","author":"J Kim","year":"2020","unstructured":"Kim J, Koo B-K, Knoblich JA. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol. 2020;21:571\u201384. https:\/\/doi.org\/10.1038\/s41580-020-0259-3.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7123_CR72","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41578-021-00279-y","volume":"6","author":"M Hofer","year":"2021","unstructured":"Hofer M, Lutolf MP. Engineering organoids. Nat Reviews Mater. 2021;6:402\u201320. https:\/\/doi.org\/10.1038\/s41578-021-00279-y.","journal-title":"Nat Reviews Mater"},{"key":"7123_CR73","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","volume":"15","author":"E Driehuis","year":"2020","unstructured":"Driehuis E, Kretzschmar K, Clevers H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat Protoc. 2020;15:3380\u2013409. https:\/\/doi.org\/10.1038\/s41596-020-0379-4.","journal-title":"Nat Protoc"},{"key":"7123_CR74","doi-asserted-by":"publisher","first-page":"1072774","DOI":"10.3389\/fonc.2022.1072774","volume":"12","author":"HD Shukla","year":"2023","unstructured":"Shukla HD, Dukic T, Roy S, Bhandary B, Gerry A, Poirier Y, et al. Pancreatic cancer derived 3D organoids as a clinical tool to evaluate the treatment response. Front Oncol. 2023;12:1072774. https:\/\/doi.org\/10.3389\/fonc.2022.1072774.","journal-title":"Front Oncol"},{"key":"7123_CR75","doi-asserted-by":"publisher","first-page":"1247125","DOI":"10.1126\/science.1247125","volume":"345","author":"MA Lancaster","year":"2014","unstructured":"Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345:1247125. https:\/\/doi.org\/10.1126\/science.1247125.","journal-title":"Science"},{"key":"7123_CR76","doi-asserted-by":"publisher","first-page":"622244","DOI":"10.3389\/fonc.2021.622244","volume":"11","author":"SS Lucky","year":"2021","unstructured":"Lucky SS, Law M, Lui MH, Mong J, Shi J, Yu S, et al. Patient-derived nasopharyngeal cancer organoids for disease modeling and radiation dose optimization. Front Oncol. 2021;11:622244. https:\/\/doi.org\/10.3389\/fonc.2021.622244.","journal-title":"Front Oncol"},{"key":"7123_CR77","doi-asserted-by":"publisher","first-page":"101483","DOI":"10.1016\/j.tranon.2022.101483","volume":"24","author":"DW Lee","year":"2022","unstructured":"Lee DW, Choi SY, Kim SY, Kim HJ, Shin D-Y, Shim J, et al. A novel 3D pillar\/well array platform using patient-derived head and neck tumor to predict the individual radioresponse. Translational Oncol. 2022;24:101483. https:\/\/doi.org\/10.1016\/j.tranon.2022.101483.","journal-title":"Translational Oncol"},{"key":"7123_CR78","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1158\/1078-0432.CCR-20-5026","volume":"27","author":"S-Y Kim","year":"2021","unstructured":"Kim S-Y, Kim S-M, Lim S, Lee JY, Choi S-J, Yang S-D, et al. Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma. Clin Cancer Res. 2021;27:4397\u2013409. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-5026.","journal-title":"Clin Cancer Res"},{"key":"7123_CR79","doi-asserted-by":"publisher","first-page":"106186","DOI":"10.1016\/j.oraloncology.2022.106186","volume":"135","author":"G Lassche","year":"2022","unstructured":"Lassche G, van Boxtel W, Aalders TW, van Hooij O, van Engen-van Grunsven ACH, Verhaegh GW, et al. Development and characterization of patient-derived salivary gland cancer organoid cultures. Oral Oncol. 2022;135:106186. https:\/\/doi.org\/10.1016\/j.oraloncology.2022.106186.","journal-title":"Oral Oncol"},{"key":"7123_CR80","doi-asserted-by":"publisher","first-page":"1190637","DOI":"10.3389\/fbioe.2023.1190637","volume":"11","author":"X He","year":"2023","unstructured":"He X, Jiang Y, Zhang L, Li Y, Hu X, Hua G, et al. Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer. Front Bioeng Biotechnol. 2023;11:1190637. https:\/\/doi.org\/10.3389\/fbioe.2023.1190637.","journal-title":"Front Bioeng Biotechnol"},{"key":"7123_CR81","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41563-020-00853-9","volume":"20","author":"KT Lawlor","year":"2021","unstructured":"Lawlor KT, Vanslambrouck JM, Higgins JW, Chambon A, Bishard K, Arndt D, et al. Cellular extrusion bioprinting improves kidney organoid reproducibility and conformation. Nat Mater. 2021;20:260\u201371. https:\/\/doi.org\/10.1038\/s41563-020-00853-9.","journal-title":"Nat Mater"},{"key":"7123_CR82","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13619-022-00137-4","volume":"11","author":"F Meng","year":"2022","unstructured":"Meng F, Shen C, Yang L, Ni C, Huang J, Lin K, et al. Mechanical stretching boosts expansion and regeneration of intestinal organoids through fueling stem cell self-renewal. Cell Regeneration. 2022;11:39. https:\/\/doi.org\/10.1186\/s13619-022-00137-4.","journal-title":"Cell Regeneration"},{"key":"7123_CR83","doi-asserted-by":"publisher","first-page":"9415","DOI":"10.7150\/thno.59533","volume":"11","author":"F Xing","year":"2021","unstructured":"Xing F, Liu Y-C, Huang S, Lyu X, Su SM, Chan UI, et al. Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform. Theranostics. 2021;11:9415. https:\/\/doi.org\/10.7150%2Fthno.59533.","journal-title":"Theranostics"},{"key":"7123_CR84","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3390\/cancers12061589","volume":"12","author":"T Suckert","year":"2020","unstructured":"Suckert T, Rassamegevanon T, M\u00fcller J, Dietrich A, Graja A, Reiche M, et al. Applying tissue slice culture in Cancer Research\u2014insights from Preclinical Proton Radiotherapy. Cancers. 2020;12:1589. https:\/\/doi.org\/10.3390\/cancers12061589.","journal-title":"Cancers"},{"key":"7123_CR85","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3390\/mi12030319","volume":"12","author":"SM Scott","year":"2021","unstructured":"Scott SM, Ali Z. Fabrication methods for microfluidic devices: an overview. Micromachines. 2021;12:319. https:\/\/doi.org\/10.3390\/mi12030319.","journal-title":"Micromachines"},{"key":"7123_CR86","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nbt.2989","volume":"32","author":"SN Bhatia","year":"2014","unstructured":"Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760\u201372. https:\/\/doi.org\/10.1038\/nbt.2989.","journal-title":"Nat Biotechnol"},{"key":"7123_CR87","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1021\/bp034077d","volume":"20","author":"A Sin","year":"2004","unstructured":"Sin A, Chin KC, Jamil MF, Kostov Y, Rao G, Shuler ML. The design and fabrication of three-chamber microscale cell culture analog devices with integrated dissolved oxygen sensors. Biotechnol Prog. 2004;20:338\u201345. https:\/\/doi.org\/10.1021\/bp034077d.","journal-title":"Biotechnol Prog"},{"key":"7123_CR88","doi-asserted-by":"publisher","unstructured":"McAleer CW, Long CJ, Elbrecht D, Sasserath T, Bridges LR, Rumsey JW, et al. Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics. Sci Transl Med. 2019;11. https:\/\/doi.org\/10.1126\/scitranslmed.aav1386.","DOI":"10.1126\/scitranslmed.aav1386"},{"key":"7123_CR89","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1146\/annurev-pharmtox-010716-104748","volume":"58","author":"R Prantil-Baun","year":"2018","unstructured":"Prantil-Baun R, Novak R, Das D, Somayaji MR, Przekwas A, Ingber DE. Physiologically based pharmacokinetic and pharmacodynamic analysis enabled by microfluidically linked organs-on-chips. Annu Rev Pharmacol Toxicol. 2018;58:37\u201364. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010716-104748.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"7123_CR90","doi-asserted-by":"publisher","first-page":"1800726","DOI":"10.1002\/admt.201800726","volume":"4","author":"Z Guo","year":"2019","unstructured":"Guo Z, Yang CT, Maritz MF, Wu H, Wilson P, Warkiani ME, et al. Validation of a vasculogenesis microfluidic model for radiobiological studies of the human microvasculature. Adv Mater Technol. 2019;4:1800726. https:\/\/doi.org\/10.1002\/admt.201800726.","journal-title":"Adv Mater Technol"},{"key":"7123_CR91","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43586-022-00118-6","volume":"2","author":"CM Leung","year":"2022","unstructured":"Leung CM, De Haan P, Ronaldson-Bouchard K, Kim G-A, Ko J, Rho HS, et al. A guide to the organ-on-a-chip. Nat Reviews Methods Primers. 2022;2:33. https:\/\/doi.org\/10.1038\/s43586-022-00118-6.","journal-title":"Nat Reviews Methods Primers"},{"key":"7123_CR92","doi-asserted-by":"publisher","first-page":"106853","DOI":"10.1016\/j.phrs.2023.106853","volume":"195","author":"M Keuper-Navis","year":"2023","unstructured":"Keuper-Navis M, Walles M, Poller B, Myszczyszyn A, van der Made TK, Donkers J, et al. The application of organ-on-chip models for the prediction of human pharmacokinetic profiles during drug development. Pharmacol Res. 2023;195:106853. https:\/\/doi.org\/10.1016\/j.phrs.2023.106853.","journal-title":"Pharmacol Res"},{"key":"7123_CR93","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1126\/science.adg6276","volume":"379","author":"M Wadman","year":"2023","unstructured":"Wadman M. FDA no longer needs to require animal tests before human drug trials. Science. 2023;379:127\u20138.","journal-title":"Science"},{"key":"7123_CR94","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3390\/cancers11101499","volume":"11","author":"N D\u00fcnker","year":"2019","unstructured":"D\u00fcnker N, Jendrossek V. Implementation of the chick chorioallantoic membrane (CAM) model in radiation biology and experimental radiation oncology research. Cancers. 2019;11:1499. https:\/\/doi.org\/10.3390\/cancers11101499.","journal-title":"Cancers"},{"key":"7123_CR95","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/cancers15010191","volume":"15","author":"D Fischer","year":"2022","unstructured":"Fischer D, Fluegen G, Garcia P, Ghaffari-Tabrizi-Wizsy N, Gribaldo L, Huang RY-J, et al. The CAM model\u2014Q&A with experts. Cancers. 2022;15:191. https:\/\/doi.org\/10.3390\/cancers15010191.","journal-title":"Cancers"},{"key":"7123_CR96","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/17425255.2021.1879047","volume":"17","author":"AK Mapanao","year":"2021","unstructured":"Mapanao AK, Che PP, Sarogni P, Sminia P, Giovannetti E, Voliani V. Tumor grafted\u2013chick chorioallantoic membrane as an alternative model for biological cancer research and conventional\/nanomaterial-based theranostics evaluation. Expert Opin Drug Metabolism Toxicol. 2021;17:947\u201368. https:\/\/doi.org\/10.1080\/17425255.2021.1879047.","journal-title":"Expert Opin Drug Metabolism Toxicol"},{"key":"7123_CR97","unstructured":"Schomaecker K, Braun F, Vazquez SM, Marmann V, Fischer T, Endepols H et al. BPD, an AR ligand for prostate carcinoma targeting. J Nucl Med. 2020;61."},{"key":"7123_CR98","doi-asserted-by":"publisher","unstructured":"L\u00f6ffler J, Herrmann H, Scheidhauer E, Wirth M, Wasserloos A, Solbach C, et al. Blocking studies to evaluate receptor-specific Radioligand binding in the CAM Model by PET and MR Imaging. Cancers. 2022;14. https:\/\/doi.org\/10.3390\/cancers14163870.","DOI":"10.3390\/cancers14163870"},{"key":"7123_CR99","doi-asserted-by":"publisher","unstructured":"Winter G, Koch ABF, L\u00f6ffler J, Lind\u00e9n M, Solbach C, Abaei A, et al. Multi-modal pet and mr imaging in the hen\u2019s egg test-chorioallantoic membrane (Het-cam) model for initial in vivo testing of target-specific radioligands. Cancers. 2020;12. https:\/\/doi.org\/10.3390\/cancers12051248.","DOI":"10.3390\/cancers12051248"},{"key":"7123_CR100","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3390\/cells9091953","volume":"9","author":"G Kalot","year":"2020","unstructured":"Kalot G, Godard A, Busser B, Pliquett J, Broekgaarden M, Motto-Ros V, et al. Aza-BODIPY: a new vector for enhanced theranostic boron neutron capture therapy applications. Cells. 2020;9:1953. https:\/\/doi.org\/10.3390\/cells9091953.","journal-title":"Cells"},{"key":"7123_CR101","doi-asserted-by":"publisher","first-page":"e2200229","DOI":"10.1002\/adbi.202200229","volume":"7","author":"P Sarogni","year":"2023","unstructured":"Sarogni P, Zamborlin A, Mapanao AK, Logghe T, Brancato L, van Zwol E, et al. Hyperthermia reduces Irradiation-Induced Tumor Repopulation in an in vivo pancreatic carcinoma model. Adv Biol (Weinh). 2023;7:e2200229. https:\/\/doi.org\/10.1002\/adbi.202200229.","journal-title":"Adv Biol (Weinh)"},{"key":"7123_CR102","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3892\/ijmm.2020.4718","volume":"46","author":"J K\u00e4hler","year":"2020","unstructured":"K\u00e4hler J, Hafner S, Popp T, Hermann C, Rump A, Port M, et al. Heterogeneous nuclear ribonucleoprotein K is overexpressed and contributes to radioresistance irrespective of HPV status in head and neck squamous cell carcinoma. Int J Mol Med. 2020;46:1733\u201342. https:\/\/doi.org\/10.3892\/ijmm.2020.4718.","journal-title":"Int J Mol Med"},{"key":"7123_CR103","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.yexcr.2014.06.010","volume":"328","author":"D Ribatti","year":"2014","unstructured":"Ribatti D. The chick embryo chorioallantoic membrane as a model for tumor biology. Exp Cell Res. 2014;328:314\u201324. https:\/\/doi.org\/10.1016\/j.yexcr.2014.06.010.","journal-title":"Exp Cell Res"},{"key":"7123_CR104","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1126\/science.1069193","volume":"296","author":"RJ Mural","year":"2002","unstructured":"Mural RJ, Adams MD, Myers EW, Smith HO, Miklos GLG, Wides R, et al. A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome. Science. 2002;296:1661\u201371. https:\/\/doi.org\/10.1126\/science.1069193.","journal-title":"Science"},{"key":"7123_CR105","first-page":"207","volume":"110","author":"EC Bryda","year":"2013","unstructured":"Bryda EC. The mighty mouse: the impact of rodents on advances in biomedical research. Mo Med. 2013;110:207.","journal-title":"Mo Med"},{"key":"7123_CR106","doi-asserted-by":"publisher","first-page":"e0156162","DOI":"10.1371\/journal.pone.0156162","volume":"11","author":"R Ramasawmy","year":"2016","unstructured":"Ramasawmy R, Johnson SP, Roberts TA, Stuckey DJ, David AL, Pedley RB, et al. Monitoring the growth of an orthotopic tumour xenograft model: multi-modal imaging assessment with benchtop MRI (1T), high-field MRI (9.4 T), ultrasound and bioluminescence. PLoS ONE. 2016;11:e0156162. https:\/\/doi.org\/10.1371\/journal.pone.0156162.","journal-title":"PLoS ONE"},{"key":"7123_CR107","doi-asserted-by":"publisher","first-page":"321538","DOI":"10.1155\/2011\/321538","volume":"2011","author":"A-L Puaux","year":"2011","unstructured":"Puaux A-L, Ong LC, Jin Y, Teh I, Hong M, Chow PKH, et al. A comparison of imaging techniques to monitor tumor growth and cancer progression in living animals. Int J Mol Imaging. 2011;2011:321538. https:\/\/doi.org\/10.1155\/2011\/321538.","journal-title":"Int J Mol Imaging"},{"key":"7123_CR108","doi-asserted-by":"publisher","first-page":"e9364","DOI":"10.1371\/journal.pone.0009364","volume":"5","author":"J-B Kim","year":"2010","unstructured":"Kim J-B, Urban K, Cochran E, Lee S, Ang A, Rice B, et al. Non-invasive detection of a small number of bioluminescent cancer cells in vivo. PLoS ONE. 2010;5:e9364. https:\/\/doi.org\/10.1371\/journal.pone.0009364.","journal-title":"PLoS ONE"},{"key":"7123_CR109","doi-asserted-by":"publisher","unstructured":"Kleynhans J, Ebenhan T, Cleeren F, Sathekge MM. Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy? Eur J Nucl Med Mol Imaging. 2024:1\u201316. https:\/\/doi.org\/10.1007\/s00259-024-06719-5","DOI":"10.1007\/s00259-024-06719-5"},{"key":"7123_CR110","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.tibtech.2017.12.001","volume":"36","author":"M Landgraf","year":"2018","unstructured":"Landgraf M, McGovern JA, Friedl P, Hutmacher DW. Rational design of mouse models for cancer research. Trends Biotechnol. 2018;36:242\u201351. https:\/\/doi.org\/10.1016\/j.tibtech.2017.12.001.","journal-title":"Trends Biotechnol"},{"key":"7123_CR111","doi-asserted-by":"publisher","first-page":"11117","DOI":"10.1038\/s41598-019-47308-z","volume":"9","author":"W Zhang","year":"2019","unstructured":"Zhang W, Fan W, Rachagani S, Zhou Z, Lele SM, Batra SK, Garrison JC. Comparative study of subcutaneous and orthotopic mouse models of prostate cancer: vascular perfusion, vasculature density, hypoxic burden and BB2r-targeting efficacy. Sci Rep. 2019;9:11117. https:\/\/doi.org\/10.1038\/s41598-019-47308-z.","journal-title":"Sci Rep"},{"key":"7123_CR112","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41585-022-00677-z","volume":"20","author":"V Sailer","year":"2023","unstructured":"Sailer V, von Amsberg G, Duensing S, Kirfel J, Lieb V, Metzger E, et al. Experimental in vitro, ex vivo and in vivo models in prostate cancer research. Nat Reviews Urol. 2023;20:158\u201378. https:\/\/doi.org\/10.1038\/s41585-022-00677-z.","journal-title":"Nat Reviews Urol"},{"key":"7123_CR113","doi-asserted-by":"publisher","first-page":"2000699","DOI":"10.1080\/2162402X.2021.2000699","volume":"10","author":"K De Veirman","year":"2021","unstructured":"De Veirman K, Puttemans J, Krasniqi A, Ertveldt T, Hanssens H, Romao E, et al. CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8\u2009+\u2009T cells and PD-L1 expression in multiple myeloma. Oncoimmunology. 2021;10:2000699. https:\/\/doi.org\/10.1080\/2162402X.2021.2000699.","journal-title":"Oncoimmunology"},{"key":"7123_CR114","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1158\/1535-7163.MCT-21-0220","volume":"21","author":"J Puttemans","year":"2022","unstructured":"Puttemans J, Stijlemans B, Keyaerts M, Vander Meeren S, Renmans W, Fostier K, et al. The road to personalized myeloma medicine: patient-specific single-domain antibodies for anti-idiotypic radionuclide therapy. Mol Cancer Ther. 2022;21:159\u201369. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0220.","journal-title":"Mol Cancer Ther"},{"key":"7123_CR115","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.neo.2016.11.001","volume":"19","author":"L Rbah-Vidal","year":"2017","unstructured":"Rbah-Vidal L, Vidal A, Billaud EMF, Besse S, Ranchon-Cole I, Mishellany F, et al. Theranostic approach for metastatic pigmented melanoma using ICF15002, a multimodal radiotracer for both PET imaging and targeted radionuclide therapy. Neoplasia. 2017;19:17\u201327. https:\/\/doi.org\/10.1016\/j.neo.2016.11.001.","journal-title":"Neoplasia"},{"key":"7123_CR116","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2967\/jnumed.119.236265","volume":"61","author":"R Hernandez","year":"2020","unstructured":"Hernandez R, Grudzinski JJ, Aluicio-Sarduy E, Massey CF, Pinchuk AN, Bitton AN, et al. 177Lu-NM600 targeted radionuclide therapy extends survival in syngeneic murine models of triple-negative breast cancer. J Nucl Med. 2020;61:1187\u201394. https:\/\/doi.org\/10.2967\/jnumed.119.236265.","journal-title":"J Nucl Med"},{"key":"7123_CR117","doi-asserted-by":"publisher","unstructured":"Chulpanova DS, Kitaeva KV, Rutland CS, Rizvanov AA, Solovyeva VV. Mouse Tumor models for Advanced Cancer Immunotherapy. Int J Mol Sci. 2020;21. https:\/\/doi.org\/10.3390\/ijms21114118.","DOI":"10.3390\/ijms21114118"},{"key":"7123_CR118","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Therapy. 2023;8:160. https:\/\/doi.org\/10.1038\/s41392-023-01419-2.","journal-title":"Signal Transduct Target Therapy"},{"key":"7123_CR119","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1158\/1078-0432.CCR-13-2611","volume":"20","author":"SJ Weroha","year":"2014","unstructured":"Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res. 2014;20:1288\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2611.","journal-title":"Clin Cancer Res"},{"key":"7123_CR120","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ijc.30472","volume":"140","author":"D Wang","year":"2017","unstructured":"Wang D, Pham NA, Tong J, Sakashita S, Allo G, Kim L, et al. Molecular heterogeneity of non-small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors. Int J Cancer. 2017;140:662\u201373. https:\/\/doi.org\/10.1002\/ijc.30472.","journal-title":"Int J Cancer"},{"key":"7123_CR121","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1078-0432.CCR-10-2224","volume":"17","author":"T John","year":"2011","unstructured":"John T, Kohler D, Pintilie M, Yanagawa N, Pham N-A, Li M, et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non\u2013small cell lung cancer. Clin Cancer Res. 2011;17:134\u201341. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2224.","journal-title":"Clin Cancer Res"},{"key":"7123_CR122","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ejca.2003.10.011","volume":"40","author":"I Fichtner","year":"2004","unstructured":"Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T, Bibby M. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer. 2004;40:298\u2013307. https:\/\/doi.org\/10.1016\/j.ejca.2003.10.011.","journal-title":"Eur J Cancer"},{"key":"7123_CR123","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.7150\/thno.32033","volume":"9","author":"J Wang","year":"2019","unstructured":"Wang J, Xing B, Liu W, Li J, Wang X, Li J, et al. Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis. Theranostics. 2019;9:3485. https:\/\/doi.org\/10.7150%2Fthno.32033.","journal-title":"Theranostics"},{"key":"7123_CR124","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00259-020-05057-6","volume":"48","author":"EAM Ruigrok","year":"2021","unstructured":"Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48:1339\u201350. https:\/\/doi.org\/10.1007\/s00259-020-05057-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7123_CR125","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-19-1098","volume":"19","author":"L Zhao","year":"2020","unstructured":"Zhao L, Chen H, Guo Z, Fu K, Yao L, Fu L, et al. Targeted radionuclide therapy in patient-derived xenografts using 177Lu-EB-RGD. Mol Cancer Ther. 2020;19:2034\u201343. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-1098.","journal-title":"Mol Cancer Ther"},{"key":"7123_CR126","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7150\/thno.21397","volume":"8","author":"S Habringer","year":"2018","unstructured":"Habringer S, Lapa C, Herhaus P, Schottelius M, Istvanffy R, Steiger K, et al. Dual targeting of acute leukemia and supporting niche by CXCR4-directed theranostics. Theranostics. 2018;8:369. https:\/\/doi.org\/10.7150%2Fthno.21397.","journal-title":"Theranostics"},{"key":"7123_CR127","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41374-018-0042-7","volume":"98","author":"T Ivanics","year":"2018","unstructured":"Ivanics T, Bergquist JR, Liu G, Kim MP, Kang Y, Katz MH, et al. Patient-derived xenograft cryopreservation and reanimation outcomes are dependent on cryoprotectant type. Lab Invest. 2018;98:947\u201356. https:\/\/doi.org\/10.1038\/s41374-018-0042-7.","journal-title":"Lab Invest"},{"key":"7123_CR128","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41698-022-00268-6","volume":"6","author":"ACH Hoge","year":"2022","unstructured":"Hoge ACH, Getz M, Zimmer A, Ko M, Raz L, Beroukhim R, et al. DNA-based copy number analysis confirms genomic evolution of PDX models. NPJ Precision Oncol. 2022;6:30. https:\/\/doi.org\/10.1038\/s41698-022-00268-6.","journal-title":"NPJ Precision Oncol"},{"key":"7123_CR129","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/ijc.32662","volume":"146","author":"J Shi","year":"2020","unstructured":"Shi J, Li Y, Jia R, Fan X. The fidelity of cancer cells in PDX models: characteristics, mechanism and clinical significance. Int J Cancer. 2020;146:2078\u201388. https:\/\/doi.org\/10.1002\/ijc.32662.","journal-title":"Int J Cancer"},{"key":"7123_CR130","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/0975-7406.124301","volume":"6","author":"TF Vandamme","year":"2014","unstructured":"Vandamme TF. Use of rodents as models of human diseases. J Pharm Bioallied Sci. 2014;6:2\u20139. https:\/\/doi.org\/10.4103\/0975-7406.124301.","journal-title":"J Pharm Bioallied Sci"},{"key":"7123_CR131","doi-asserted-by":"crossref","unstructured":"Ganguly K, Batra SK, Kaur S. Mouse models of pancreatic cancer: An ever-emerging arm of cancer drug discovery. Animal Models in Cancer Drug Discovery: Elsevier; 2019; pp. 249\u2013\u200966.","DOI":"10.1016\/B978-0-12-814704-7.00010-6"},{"key":"7123_CR132","doi-asserted-by":"publisher","unstructured":"Li Z, Zheng W, Wang H, Cheng Y, Fang Y, Wu F, et al. Application of animal models in cancer research: recent progress and future prospects. Cancer Manage Res. 2021;2455\u201375. https:\/\/doi.org\/10.2147\/CMAR.S302565.","DOI":"10.2147\/CMAR.S302565"},{"key":"7123_CR133","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","volume":"163","author":"C-P Day","year":"2015","unstructured":"Day C-P, Merlino G, Van Dyke T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell. 2015;163:39\u201353. https:\/\/doi.org\/10.1016\/j.cell.2015.08.068.","journal-title":"Cell"},{"key":"7123_CR134","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature13906","volume":"516","author":"FJ S\u00e1nchez-Rivera","year":"2014","unstructured":"S\u00e1nchez-Rivera FJ, Papagiannakopoulos T, Romero R, Tammela T, Bauer MR, Bhutkar A, et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature. 2014;516:428\u201331. https:\/\/doi.org\/10.1038\/nature13906.","journal-title":"Nature"},{"key":"7123_CR135","doi-asserted-by":"publisher","first-page":"137","DOI":"10.15252\/emmm.201606857","volume":"9","author":"K Kersten","year":"2017","unstructured":"Kersten K, de Visser KE, van Miltenburg MH, Jonkers J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med. 2017;9:137\u201353. https:\/\/doi.org\/10.15252\/emmm.201606857.","journal-title":"EMBO Mol Med"},{"key":"7123_CR136","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.drudis.2013.07.007","volume":"18","author":"N Scheer","year":"2013","unstructured":"Scheer N, Snaith M, Wolf CR, Seibler J. Generation and utility of genetically humanized mouse models. Drug Discovery Today. 2013;18:1200\u201311. https:\/\/doi.org\/10.1016\/j.drudis.2013.07.007.","journal-title":"Drug Discovery Today"},{"key":"7123_CR137","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3389\/fgene.2018.00240","volume":"9","author":"B Roy","year":"2018","unstructured":"Roy B, Zhao J, Yang C, Luo W, Xiong T, Li Y, et al. CRISPR\/Cascade 9-Mediated Genome Editing-challenges and opportunities. Front Genet. 2018;9:240. https:\/\/doi.org\/10.3389\/fgene.2018.00240.","journal-title":"Front Genet"},{"key":"7123_CR138","doi-asserted-by":"publisher","unstructured":"Wang L, Dou X, Chen S, Yu X, Huang X, Zhang L, et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023;41. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.019. 1294\u2013\u2009308. e8.","DOI":"10.1016\/j.ccell.2023.04.019"},{"key":"7123_CR139","doi-asserted-by":"publisher","first-page":"784947","DOI":"10.3389\/fonc.2021.784947","volume":"11","author":"MM Cogels","year":"2021","unstructured":"Cogels MM, Rouas R, Ghanem GE, Martinive P, Awada A, Van Gestel D, Krayem M. Humanized mice as a Valuable Pre-clinical Model for Cancer Immunotherapy Research. Front Oncol. 2021;11:784947. https:\/\/doi.org\/10.3389\/fonc.2021.784947.","journal-title":"Front Oncol"},{"key":"7123_CR140","doi-asserted-by":"publisher","first-page":"8599","DOI":"10.3390\/ijms23158599","volume":"23","author":"AC Beenen","year":"2022","unstructured":"Beenen AC, Sauerer T, Schaft N, D\u00f6rrie J. Beyond cancer: regulation and function of PD-L1 in health and immune-related diseases. Int J Mol Sci. 2022;23:8599. https:\/\/doi.org\/10.3390\/ijms23158599.","journal-title":"Int J Mol Sci"},{"key":"7123_CR141","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1158\/2326-6066.CIR-18-0280","volume":"7","author":"S Heskamp","year":"2019","unstructured":"Heskamp S, Wierstra PJ, Molkenboer-Kuenen JDM, Sandker GW, Thordardottir S, Cany J, et al. PD-L1 microSPECT\/CT imaging for longitudinal monitoring of PD-L1 expression in syngeneic and humanized mouse models for cancer. Cancer Immunol Res. 2019;7:150\u201361. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0280.","journal-title":"Cancer Immunol Res"},{"key":"7123_CR142","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00259-017-3803-4","volume":"45","author":"CG England","year":"2018","unstructured":"England CG, Jiang D, Ehlerding EB, Rekoske BT, Ellison PA, Hernandez R, et al. 89 Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging. 2018;45:110\u201320. https:\/\/doi.org\/10.1007\/s00259-017-3803-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7123_CR143","doi-asserted-by":"publisher","unstructured":"Stribbling SM, Beach C, Ryan AJ. Orthotopic and metastatic tumour models in preclinical cancer research. Pharmacol Ther. 2024;108631. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108631.","DOI":"10.1016\/j.pharmthera.2024.108631"},{"key":"7123_CR144","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.21873\/anticanres.14540","volume":"40","author":"YM Morillon","year":"2020","unstructured":"Morillon YM, Sabzevari A, Schlom J, Greiner JW. The development of next-generation PBMC humanized mice for preclinical investigation of cancer immunotherapeutic agents. Anticancer Res. 2020;40:5329\u201341. https:\/\/doi.org\/10.21873\/anticanres.14540.","journal-title":"Anticancer Res"},{"key":"7123_CR145","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s42003-021-02527-x","volume":"4","author":"JA McGovern","year":"2021","unstructured":"McGovern JA, Bock N, Shafiee A, Martine LC, Wagner F, Baldwin JG, et al. A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells. Commun Biology. 2021;4:1014. https:\/\/doi.org\/10.1038\/s42003-021-02527-x.","journal-title":"Commun Biology"},{"key":"7123_CR146","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, De Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07123-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07123-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07123-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:52:40Z","timestamp":1751435560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07123-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":146,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7123"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07123-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}